Rinvoq 2021 report




Published July 2022 • 27 Pages

The 5 Key Questions Addressed by this Report:

  • How many physicians were reached by Rinvoq through reportable promotional activity in 2021 and how does this compare to its peer set in the Psoriatic Arthritis and Rheumatoid Arthritis markets?
  • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
  • How does AbbVie’s depth of coverage vary within key specialties (e.g., Rheumatology, Nursing, Physician Assistant, Internal Medicine, and Dermatology) and how does this compare to its peers and the overall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for Rinvoq throughout the year (e.g., monthly, quarterly, annually)?
  • Who were the most frequent meal recipients and top paid speakers for Rinvoq in 2021?

Data Sources and Methodology:

  • MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
  • Over 41,900 paid interactions across 4,490 physicians made on behalf of Rinvoq were carefully examined to support our analysis. In addition, interaction data from 23 peer products (e.g. Actemra, Avsola, Cimzia, Cosentyx, Enbrel, Humira, Ilaris, Inflectra, Kevzara, Kineret, Naprelan, Olumiant, Orencia, Otezla, Rayos, Remicade, Renflexis, Rituxan, Simponi, Stelara, Taltz, Tremfya, and Xeljanz ) was leveraged to provide benchmarking and market insights.